Compare Bio Protocol (BIO) vs Immunefi (IMU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio Protocol vs Immunefi — how do they compare? Bio Protocol trades at Rp442.86 (market cap Rp1,01T, Rp176,29M 24h volume), while Immunefi trades at Rp24.67 (market cap Rp27,03M, Rp39,91M 24h volume). The key difference: Bio Protocol is far larger — about 37365.9× Immunefi's market cap, and Bio Protocol's circulating supply is 2,3B / 3,3B BIO (69%) versus 873,4M / 10B IMU (9%) for Immunefi. Which is the better fit depends on your goals — on Pluang, investors hold Bio Protocol for 18 Days and Immunefi for 5 Days on average.
| BIO | IMU | |
|---|---|---|
Market Cap | Rp1,01T | Rp27,03M |
Volume (24h) | Rp176,29M | Rp39,91M |
Circulating Supply | 2,3B / 3,3B BIO (69%) | 873,4M / 10B IMU (9%) |
Typical Hold Time | 18 Days | 5 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio Protocol (BIO) trades at Rp424.33 with a market cap of Rp965.85M, showing neutral technical signals amid bearish moving averages. The token's circulating supply of 2.3M out of 3.3M max indicates 69% circulation with an average hold time of 17 days. Recent technical indicators show mixed signals with RSI in neutral territory while ADX suggests some buying momentum. Support and resistance levels are well-defined between Rp398 and Rp500.
Overall outlook remains neutral with key opportunities in protocol adoption growth, though risks include limited liquidity and typical crypto volatility. Investors should monitor network activity closely as the token operates in a competitive blockchain ecosystem without major recent protocol updates.
Immunefi (IMU) presents a unique crypto asset with a modest market cap of Rp27.03M and only 9% circulating supply, indicating significant token lockup. The 5-day average hold time suggests short-term trading activity. Current technical analysis is limited due to missing price data, but the low circulation rate and small market cap point to high volatility potential. Recent news coverage appears to focus on corporate equity analysis rather than blockchain fundamentals, creating information asymmetry for crypto investors.
Overall outlook remains speculative with limited fundamental data. Key opportunity lies in potential token unlocks and ecosystem growth, while major risks include extreme volatility from low liquidity, regulatory uncertainty, and lack of clear crypto-specific utility. Investors should approach with caution given the asset's early stage and limited market data availability.
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Bio Protocol
BIO Protocol enables global communities of scientists, patients, and investors to collectively fund, develop, and co-own new drugs and therapeutics through its network of Biotech Decentralized Autonomous Organizations (BioDAOs). The protocol's innovative approach addresses critical gaps in traditional scientific funding, particularly in areas such as rare diseases, longevity research, and emerging health challenges.
Read more on BIO →About Immunefi
Immunefi is a security-focused ecosystem token designed to reward contributions to blockchain safety. It aligns protocols, researchers, and communities through bug bounties, staking, and governance incentives. The ecosystem also integrates AI to enhance threat detection and scale protection as the on-chain economy grows.
Read more on IMU →
